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Abstract 
Whole genome or exome sequencing enables the fast generation of large 
volumes of data and is currently a hot topic in research. This technique has the subject 
of extensive research and has vast applications in healthcare and medicine. Next 
generation sequencing (NGS) has the advantage of providing large length reads when 
compared to the traditional method of Sanger Sequencing. NGS enables the 
identification of genetic disease-causing variants, thus, improving the quality of 
healthcare, diagnostics and biomedical research. 
One of the major challenges of NGS is the analysis of large data outcomes. 
The diversity in DNA library preparation methods for various available platforms 
may result in data inaccuracies. Furthermore, the disparity in variant calling 
accuracies as a result of using diverse algorithms complicates the process of NGS data 
analysis. As a result, there is a large possibility for false positive and/or false negative 
results due to alignment and/or chemistry errors. 
In this project, we utilized the MiSeq platform that was selected based on its 
cost effective properties and ability to provide rapid genetic analysis. The autism 
panel is used in this study to assist the investigation of genomic features associated 
with autism by targeting 101 genes linked specifically to Autism. Here, we 
hypothesized that we could devise NGS analysis criteria to distinguish false positive 
and/or false negative sequencing calls to improve the quality of the generated 
sequencing data. Four Autism patients cohort of Arab descent have been used as a 
model for this research. We were able to prove our hypothesized criteria by validating 
the detected variances by Sanger Sequencing. 
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1. Introduction: 
DNA sequencing is used to determine the exact order of nucleotide within the 
DNA and/or RNA molecules. This technique provides scientists in the biological 
fields with access to molecular cloning and breeding which helps them in not only 
detecting diseases but also identifying genes behind these diseases. Most importantly 
this technique is capable of increasing life quality by decoding some of the life 
ambiguities [1]. The first and most significant achievement of the DNA sequencing 
project was the human genome project that has a cost of three billion dollars. This 
project started 13 years ago and was finalized in 2003. Human genome project was 
established to study the genetic structure of human as well as clarifying the human 
development[2]. This project was developed with excellent capabilities to illustrate 
lots of human disease mysteries by understanding the disease genotype therefor 
precisely describing the phenotypic structure of these diseases.  Upon discovery this 
achievement showed great potential in improving disease prevention and treatment 
[3]. The power of DNA sequencing is to have a method that is easy to access, fast, 
accurate and most importantly cost-effective. This is what lead scientist to think of 
such a method that could aid obtaining this goal.   
Sequencing technology was first developed between 1964 and 1965, by an 
American biochemist, Robert Holley and his colleagues, who sequenced a nucleic 
acid making them the first in the field to do sequencing methods for tRNA [4]. 
However, in 1975, Frederick Sanger thought of sequencing the DNA by using the 
chain-termination method, since then this gold method has been known as Sanger 
sequencing (first sequencing generation)[5]. The strength behind Sanger sequencing is 
  
 2 
the fact that it is (i) very accurate, (ii) highly efficient, (iii) reduces the radioactivity 
and  (iv) can perform long read length (800-1000bp) [6]. Despite being a robust 
sequencing method with high throughput data, Sanger sequencing was limited by the 
fact that it is very expensive and takes a long time to performs sequencing. These 
obstacles lead the scientist to think of a new generation of sequencing that could 
overcome these mentioned problems. This paves the way for invention the Next 
Generation Sequencing (NGS). 
  The first encounter with NGS or the so-called second-generation sequencing 
was between 1994-1998, however it is first official existence commercially was not 
until 2005 [7]. Lynx Therapeutics (USA) Company produced the first NGS product in 
2000 now these products are owned by Illumina. NGS is also known as the Massively 
Parallel Signature Sequencing platforms (MPSS) for its ability to perform the 
sequencing using massively parallel procedure; which facilitates the sequencing with 
1 million to 43 billion short readouts (50-400 bases each) per instrument run [8].  
After discovering MPSS and specifically by 2004, 454 Life Sciences (Branford, CT, 
USA) took the advantage of producing a new version of pyrosequencing that was able 
to reduce the costs of sequencing to 6-fold less when compared to automated Sanger 
sequencing (Life Sciences, a Roche Company). In 2006, after NGS was officially 
commercially available, Genome Analyzer was released by Solexa, followed by the 
establishment of Sequencing by Oligo Ligation Detection (SOLiD), which was 
provided by Agencourt [1, 9]. 
Nowadays, NGS is highly used in the clinical and medical field specifically in 
the area of identification of genetic diseases, which will improve the quality of life 
and healthcare. That is due to its cost-effectiveness, time efficiency, and provision of 
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high throughput data properties in comparison to Sanger Sequencing. Using NGS 
brought lots of challenges; one of the greatest challenges was the analysis of large 
data outcomes drawing attention to the fact that the diversity of the methods used to 
prepare DNA library for various available platforms may result in data inaccuracies 
[10]. Furthermore, the disparity in variant calling accuracies as a result of using 
various algorithms complicates the process of NGS data analysis[11]. As a result, 
there is a larger possibility for false positive and/or false negative results due to 
alignment and/or chemistry errors [12]. Therefore, in this project, we focused in 
utilizing the MiSeq platform. This platform was selected for its cost effective 
properties as well as its ability to provide rapid genetic analysis [13]. In this project, I 
will be using the autism panel to assist in the investigation of genomic features 
associated with Autism Spectrum Disorders (ASD) by targeting 101 genes linked 
specifically to ASD [14-16].  
Herein, we hypothesize that devising NGS analysis criteria to identify false 
positive and/or false negative sequencing calls is possible. By doing so, we can 
improve the quality of the generated sequencing data. In this project we will be 
utilizing four autism patient cohort of Arab descent as a research model. The findings 
of this research can serve in improving the identification of disease causing variants 
and increasing the power of diagnosing not only ASD but also other diseases using 
this technique. 
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1.1 Hypothesis and Aims: 
1.1.1 Hypothesis: 
“To evaluate the autism panel’s genes, certain parameters and thresholds will be 
applied on the MiSeq NGS output data as indicated by quality indices. We hypothesize 
a significant increase in the reliability of the generated sequencing data and expect to 
narrow down the amount of data generated by using a specific analysis pipeline to 
identify and minimize the amount of false positives and/or false negatives in the 
results”. 
 
1.1.2 Aims 
To prove this hypothesis, following aims were indicated: 
x Aim 1: To produce MiSeq NGS data for four Arab patients with autism 
utilizing a commercially provided autism panel. 
x Aim 2: Identify the variants that are called in each patient and determine the 
quality indices. 
x Aim 3:  To validate these variant calls using targeted Sanger sequencing. 
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2. Literature Survey: 
NGS is a new technology in the genetics filed, which promises a new, fast, 
and cost-effective way in diagnosis and selection of treatment in the future. This could 
be used for many genetic diseases in detecting the gene or genes causing the disease, 
which will lead to decode the mysteries of life and increase the quality of life [1]. It 
helps mainly in the heterogeneous diseases [17]. The significance of using NGS, is 
that it could provide more accurate result due to deep coverage in the sequencing the 
data [17]. There are different types of NGS, each performing a specific function and 
has specific characteristic features. So the type or platform to be used depends on the 
research question and the research application. Below is a brief description of the 
major NGS systems: 
2.1 Roche 454 System: 
Roche 454 System was the first NGS system that was commercially produced. 
It depends on the use of pyrosequencing technology that detect releasing of 
pyrophosphate during nucleotide incorporation [18]. In this system the DNA 
samples are first prepared in the library with 454-specific adaptors. Then they are 
denatured into single strand and captured by amplification beads which are then 
followed by PCR emulsion [19]. To complement the bases of the template strand 
on a picotiter plate, one of the following nucleotides (dNTP’s) dATP, dGTP, 
dCTP and dTTP is added with the assistance of sets of enzymes such as; ATP 
sulfurylase, luciferase, luciferin, DNA polymerase, and adenosine 5′ 
phosphosulfate (APS) that will lead to release pyrophosphate (PPi) equals to the 
amount of the incorporated dNTP’s. The release of PPi results in ATP production 
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that converts the luciferin into oxyluciferin, which then results in generating 
visible light, however, in the case of unmatched bases, apyrase will degrade it. 
After that, the reaction system will be completed by the addition of another dNTP, 
and then the pyrosequencing reaction is repeated [20]. 
The main three advantages of Roche 454 System are (a) the length of its 
readouts which is about 700 bp with 99.9%, accuracy, (b) it is quite fast requiring 
only 10 hours to finish and (c) it provides a cost-effective sequencing system 
[21]. 
 
2.2 ABI SOLiD System: 
In 2006, Applied Biosystems purchased a sequencing system called 
Sequencing by Oligo Ligation Detection (SOLiD). SOLiD technology depends on 
the ligation sequencing technique that relies on using a specific flowcell to do 
sequencing of the DNA libraries. This requires having 8 base-probe ligation sites; 
the first base which is the ligation site, the fifth base which is cleavage site, and in 
the last base there are 4 different fluorescent dyes linked to it .The fluorescent 
signal will be detected when the probes bind to the template strand and then 
removed by the cleavage of the last 3 bases. Then the sequencing of the fragment 
will be gathered using ladder primer sets [9]. 
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2.3 Illumina GA/HiSeq System: 
Solexa first produced the Genome Analyzer (GA) in 2006. After that, 
Illumina bought it in 2007. GA sequencing system uses the sequencing by 
synthesis (SBS) technique. In this system, fixed adaptors are first attached to the 
DNA libraries, which are then denatured into single strands and attached to the 
flowcell part of the machine. Using the method of bridge amplification forms then 
clusters of DNA clones, linearization enzyme is next used to splice the library into 
single strands before proceeding into the sequencing steps. To complete the single 
strand template that will be used in the sequencing step, four kinds of dNTP’s 
(ddATP, ddGTP, ddCTP and ddTTP) containing different cleavable fluorescent 
dye and a removable blocking group are added one base each time. Which enables 
signal detection by a (charge-coupled device) CCD [9]. 
 
2.4 Compact PGM Sequencers: 
2.4.1 Ion PGM from Ion Torrent 
Ion Personal Genome Machine (PGM) launched by Ion Torrent is the first 
sequencing machine that does not use fluorescence and camera scanning for 
sequencing because it is based on using semiconductor-sequencing technology. 
Protons are released when the polymerase adds dNTP’s to the DNA strand. PGM 
detect the change in pH to recognize if a nucleotide is added or not. Each time the 
chip of the system adds a nucleotide after another and the detected signal will be 
in the form of voltages. If the nucleotide did not bind there will be no voltage and 
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therefore no signal, on the other hand, if there are two nucleotides bound, then 
two voltages will be detected [22]. 
 
2.4.2 MiSeq: 
MiSeq, also produced by Illumina, depends on the sequencing by synthesis 
(SBS) technology, which is similar to the GA/HiSeq. Unlike the GA/HiSeq, 
MiSeq does not sequence large fragments making it much faster than the 
GA/HiSeq with a processing time of around 8 hours. MiSeq is used in sequencing 
smaller fragment sizes such as sequencing of amplicons, and small genome; 
making it perfect for sequencing targeted genes, metagenomics, targeted gene 
expression, and HLA typing [23]. MiSeq has the ability to detect different 
mutations, including the point mutation and any small In-dels, making it able to 
perform the same function of Sanger sequencing but with high efficiency[24]. 
The read length that can be carried out by MiSeq ranges between 36 bp single 
reads which are about (120 MB output) up to 2 × 150 paired-end reads which are 
about (1–1.5 GB output). Because of this improvement of the read length, the 
resulting data from MiSeq will act better in contig assembly if compared to other 
systems using the same method technology such as HiSeq [1]. Comparison 
between the different NGS platforms based on different features is summarized 
on (Figure 1). 
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Figure 1. Comparison between the different types of the Next generation sequencing 
(NGS).  [25] 
 
The impact of using MiSeq appears clearly in many aspects, especially in 
clinical fields. MiSeq depends on mainly in the targeted genome methods, which aids 
in targeting only the anticipated region of the genome that could cause the disease. 
This occurs, by designing specific panel that targets hundreds of genomic regions, 
which are expected to cause the investigated disease. Targeted sequencing panels 
could help in disease diagnosis and most importantly identifying the mutations 
causing that disease. In addition it could assist in the process of choosing the best 
therapeutic decision in many diseases like cancer [26], and acute myeloid leukemia 
[27].  
In the vaccination field, MiSeq system could be used widely for improving the 
identification of epitopes of phage-displayed antigen-specific libraries. This could be 
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done by targeting the model antigen regions by serum antibodies in immunized 
(vaccinated) people and then checking the immunoreactivity developed in the 
hundreds of antigenic fragments [28].  MiSeq is also used in immunology; nowadays 
it has a great role in detecting sickle cell anemia in the fetus during pregnancy, by 
obtaining maternal plasma and checking the fractional fetal DNA concentration. This 
is achieved by applying the targeted sequencing property of the MiSeq for the 
amplicons of the fetus that contain single-nucleotide polymorphisms [29].  
The agricultural field was also hit by MiSeq system in many aspects all-
aiming in increasing the food safety and quality criteria. One of the most important 
aspects to do so is to detect specific taxa of microorganism from the complex 
environment that could affect the growth of some vegetables. Detecting Salmonella 
strains in tomatoes is a known example of the benefits of applying MiSeq system to 
target a specific organism from a complex microenvironment and identify where it 
came from and whether it was during enrichment or before enrichment in order to 
know the type of microorganism that affects tomato and in which stage [30]. 
MiSeq has been widely used in oncology, specifically in the aspects of (i) 
cancer treatments, (ii) drug designing, (iii) the use of cancer drugs, (iv) patients 
response to the drug, (v) in the classification of tumors and (vi) in the identification of 
the rare somatic mutation that may cause the tumors. Also MiSeq could be used in 
differentiation between somatic and germline mutation which may help in identifying 
the causing mutation for the disease. In the field of cancer research, although the 
usefulness of MiSeq in the evolution of personalized medicine and finding the 
suitable biomarkers, still there are some limitations for its using as capturing 
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techniques in cancer, one of these limitations is the quality of DNA which is mainly 
low [31]. 
Despite the fact that MiSeq has great impact in the clinical field and it could 
help humanity in diagnosing mysterious diseases, this system is capable of generating 
huge amounts of data, which necessitates the need of using filtering criteria in order to 
get the wide-ranging benefits out of this important sequencing system. These criteria 
depend on the quality of the data delivered and the target depth of the coverage data, 
i.e. how often a specific target is read and sequenced because DNA is sequenced 
multiple times during the sequencing process, which increases the rate of error that 
may occur. The median coverage differs among different users, some users rely on 
10-fold (10X) others rely on 20-fold (20X) or 30- folds (30X) at > 90% of bases 
covered as minimum coverage in quality assemblies [32]. The importance of these 
folds is to assemble properly and find the true variants with excluding the encountered 
errors which increases the mutation detection rate [31]. 
In comparison between different platforms which are based on targeted 
genome like Ion PGM and MiSeq (Figure 2), it was reported that the score of mean 
base-call quality gained from MiSeq was higher through the entire reads and the 
scatterings within the reads were small at specific positions; interestingly these reads 
were the opposite when Ion PGM was used. The read lengths obtained by MiSeq were 
consistent in lengths, while with Ion PGM they were widely distributed. Therefore it 
was concluded that the base call quality is higher when using MiSeq [17]. 
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Figure 2.Comparison between PGM and MiSeq sequencing performance [17]. 
 
 
Like any new technology, NGS has many advantages and disadvantaged. 
Starting with the encountered advantages, first seen an advantage in the throughput 
data they generated that are much higher relative to the classical sequencing. For 
example, massive parallel sequencing has a capacity of hundreds of thousands or 
millions of templates. The second advantage is reducing of the representation bias in 
template libraries during the PCR amplification step. The third and the most important 
advantage is that NGS is both cost effective and time efficient, because it needs fewer 
reagents than the needs of a classical way of sequencing.  
For the disadvantages and limitations that are faced while using the NGS, the 
first point is the fact that it generates short reads. This necessitates the need for an 
earlier genome sequenced for the new strains to be re-sequenced to detect the point 
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mutations. The second point is the repetition of regions, which is difficult to be 
gathered if the size of the fragments exceeds the average, read length. Third point is 
the preparation of the libraries, which needs lots of controlled steps like 
fragmentation, adaptor ligation and PCR amplification. This will need to control the 
size of the fragments initially to avoid any pitfalls that they could face. Finally, the 
errors and artifacts that are produced by NGS because of the high throughput data 
generated [33]. 
In our project we used one of the genetic diseases that could be diagnosed by 
NGS, which is Autism Spectrum Disorders (ASD). ASD is a group of 
neurodevelopmental disorders that share common features such as social and 
language impairment, repetitive and stereotypic behaviors. It had been found first by 
Kanner and then Asperger in 1944 and 1943 [34, 35]. The prevalence of ASD 
worldwide is significantly increasing with having a 1 in 68 children occurrence 
nowadays; also ASD is more common in males than females. ASD is a complex 
inheritance and genetic heterogeneity, and frequently it is consistent with other 
diseases such as intellectual disability, seizure disorders, and Fragile-X [36]. NGS 
have been used broadly as a genetic technology in diagnosis and identification of 
genetic causes of ASD and expand the understanding of the disease, by recognizing 
novel genetic loci and risk factors, as well as chromosomal changes, which is known 
as copy number variations (CNVs). Starting by using Oligo in-silico synthesized 
microarray (OISM) platforms [37], then by using next-generation sequencing 
technologies (NGSTs) which have been employed in the last two to three decades. 
Although NGS has been used in high genome coverage and sensitivity to study ASD 
intensively [38], the genetic cause of the majority of the ASD is elusive [39]. 
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ASD diagnosis is still a challenge because there is no specific medical 
laboratory test such as blood or urine analyses that could be used to identify it. Until 
today the gold standard diagnosis methods for ASD relies on the Autism Diagnostic 
Observation Schedule (ADOS), which includes behavioral evaluations and the Autism 
Diagnostic Interview (ADI). In addition, Social Communication Questionnaire 
(SCQ54) can be used, which is a survey test used as an initial screening tool. 
Therefore, using platforms such as microarrays and sequencing will help more in 
illustrating the copy number variations (CNV) that have a high impact on shaping our 
individuality. However, the problem with using microarray platforms seen in 
encompassing only a few hundreds to thousands of large BAC (Bacterial Artificial 
Chromosome) clones [40]. Consequently, the critical genome locations are not 
covered because there is no enough BAC coverage. While recently, NGS became 
wildly used because of its fast sequencing ability of the whole genome as well as 
costing less by sequencing many individuals DNA in one single platform in few days. 
CNV is used to define structural gain or loss of genomic segments that fall into a 
group between 1,000 base pairs to 5 megabases [41]. However, with the discovery of 
NGS the definition has become wider to include smaller variations that help in the 
identification of several CNVs at different scales and distinguishing polymorphic 
CNVs from harmful ones. 
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3. Materials and Methods: 
3.1 Patients and Ethics statement: 
QBRI institutional review board has approved the project. In this study a total 
of 4 independent ASD patients were used. DNA was obtained from peripheral blood 
leukocytes for all investigated patients after informed consent or informed parental 
consent for all minors.  
 
3.2 Next Generation Sequencing using the MiSeq platform: 
Library preparation and sequencing were performed on the MiSeq platform 
(illumina, San Diego, CA, USA) according to the manufacturer’s specifications and 
guidelines of Autism Panel-TruSight Rapid Capture Enrichment kit (illumina) as 
follows: 
3.2.1 Library preparation and DNA enrichment: 
For sample preparation, TruSight Rapid Capture sample preparation kit 
used (illumine). 50ng/ µl of DNA was used as a starting genomic material and was 
quantified for each sample. This followed by DNA shearing process step by using 
an enzymatic DNA fragmentation.  
 
3.2.1.1 Tagment Genomic DNA: 
The sheared DNA will be used for the tagmentation step by adding 25µl of 
Tagment DNA buffer (illumina) to each well of the NLT (Nextera Library 
Tagment ) plate containing the samples, then 15µl of Tagment DNA Enzyme 1 
(illumina) was added also to the samples. After that, the plate was sealed and put 
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in the centrifuge at 280g for 1 minute. Then the plate was pre-heated by using 
microheating system and is incubated at 58 °C for 10 minutes. After that, 15µl of 
Stop Tagment buffer (illumina) was added to the samples on the plate and the 
plate was shaken by using microplate shaker at 1800rpm for 1 minute. This step 
was followed by centrifugation of the plate at 280g for 1 minute then incubation at 
room temperature for 4 minutes. Samples were then tagged by unique barcode 
indices and common adapter sequences were added to the ends for each 
fragmented sample.  
 
3.2.1.2 Purification of the tagmented DNA: 
   The tagmented DNA is purified from the unbound DNA fragments and 
adaptors which can bind tightly to DNA ends, in which might interfere with 
downstream processes if not removed. This was done by adding 65 µl of well- 
resuspended sample purification beads to each well of the NLT plate. The plate 
was shaken on a microplate shaker at 1800 rpm for 1 minute, and then incubated at 
room temperature for 8 minutes, followed by centrifugation at 280g for 1 minute. 
The plate was then placed on magnetic stand for 2 minutes, after that 200µl of 
freshly prepared 80% ethanol (EMSURE) was added to each well without 
disturbing the beads. After 30 seconds incubation, the 80% ethanol was removed 
from each well. Then the plate was incubated at room temperature for 10 minutes 
to dry on the magnetic stand. After the incubation time completed, 22.5µl of 
suspension buffer was added to each well of NLT plate. 
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3.2.1.3 PCR clean up: 
After that, this step was subsequently followed by library pooling step 
(combine multiple libraries with different indices into a single pool) and the first 
amplification via limited PCR cycle program. The PCR step is critical since it is 
also adds index 1 (i7) and index 2 (i5) that are sequencing primers needed for 
sequencing, as well as common adapters (P5 and P7) that required for cluster 
generation and sequencing.  After that, PCR purification was performed by using 
AMPure XP Beads (illumina) to purify the library DNA, and provides a size 
selection step that removes very short library fragments from the population.  
 
3.2.1.4 Hybridization Step: 
Consecutively, this was followed by hybridization process, which was 
known as enrichment capture of targeted regions.  This was performed by using 
TruSight Rapid capture kit of Autism panel where the purified DNA library was 
mixed with the capture probes of targeted regions (TruSight-Autism panel) for the 
recommended hybridization time by using HSP plate NEH1 (Nextra Enrichment 
hyb1, illumina). This should be done to makes sure that targeted regions bind to 
the capture probes thoroughly (Table 1). The TruSight Autism covers the genomic 
landscapes of known reported or related genes (101) that linked to Autism. 
Immediately, this step followed by addition of 250µl streptavidin magnetic beads 
(SMB)(illumina) to capture enriched probes that contain the regions of interest. 
Then, three washing steps were performed by using 200µl of Enrichment wash 
solution (illumina) to remove the non-specific binding from the beads. 
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Later on, the enriched libraries were then eluted from the beads and 
prepared for a second hybridization to allow for further targeted regions 
enrichment by using Enrichment elution buffer 1 and 2N NaOH (Table 2). In this 
step, the library elution was mixed again with the capture probes of target regions 
and was also followed by second washing and capturing buffers. Finally, second 
PCR was performed to amplify and prepare the enriched DNA library for 
sequencing process in MiSeq machine. 
 
 
Table 1. Reagents for library preparation for MiSeq that added to each well for 
hybridization step. 
Reagent Volume (µl) 
DNA Library sample or library pool from NLS plate 40 
Enrichment Hybridization Buffer 50 
TrueSight Content Set CSO 10 
Total Volume per Sample 100 
 
 
Table 2. Reagents for enrichment step in MiSeq that added to each well for Elution 
step. 
Reagent Volume (µl) 
Enrichment Elution Buffer 1 28.5 
2N NaOH 1.5 
Total Volume per Sample 30 
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3.2.2 Clustering generation: 
After library preparation, the enriched libraries were loaded into the MiSeq 
flowcell chip (illumina) according to the manufacture guidance of MiSeq machine 
preparation where the cluster generation was processed. The flowcell is a glass 
slide with lanes, each lane is a channel coated with two types of oligos in which 
each fragment/molecule was isothermally attached to these oligos to allow 
fragments amplification later on. The attachment of these fragments is known as 
the hybridization step that enriches the fragments attachment to the oligos on the 
chip surface. These oligos are complementary to the adapter region on one of 
fragment strand. Continuously, the amplification step was followed where the 
polymerase creates a complement on the hybridized fragment. After that, the 
double stranded molecule is denatured and the original strand is washed away. 
Then, the strand is clonally amplified to form bridge amplification. These steps 
were repeated for the second adapter region that is hybridized and amplified to the 
second type of oligos on the flowcell, resulting in two strands attached to flow 
cell. Repeating the process to form the clonal amplification, which contains 
millions of clusters. Finally, the revers strand at each oligos type was cleft away.   
 
3.2.3 Sequencing: 
After cluster generation, sequencing begins with the extension of 
sequencing primer to produce the first read. With each cycle, four fluorescently 
tagged nucleotides compete for the addition of growing chain and one that is 
complementary to sequence the template will be incorporated. After addition of 
each nucleotide, the clusters are excited by a light source, and characteristic 
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fluorescents signals are emitted, this process is called sequencing by synthesis. 
The number of cycles determines the length of the reads. The emission 
wavelength along with the signal intensity determines the base calls. For a given 
clusters, all identical strands are read simultaneously. Hundreds of millions of 
clusters are sequenced in a massively parallel process. Once the first read finishes, 
the product is washed away and the index1 primer will hybridize to the template. 
The second read is generated similar to the first read. After completing the second 
read, the product will be washed away and the template then folded over and 
binds a second Oligo on the flow cell. Then index2 is read as the same manner as 
index1 then the product will be washed away and the polymerases will extend the 
template and form paired-end sequencing. This double stranded DNA is denatured 
and the forward strand is washed away, leaving the reverse strand where the 
second read start by the introduction of read 2 primer sequencer, in the same 
manner as read 1. This entire process generates billions of short reads representing 
all the fragments that will be saved in FASTQ format. (Figure 3) Summarizing the 
workflow of the MiSeq.  
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Figure 3: Workflow of next generation sequencing that based on the mechanism of 
sequencing by synthesis like the MiSeq [42]. It shows the steps starting from DNA till 
the sequencing alignment and data analysis. 
 
 
3.2.4 Bioinformatics: 
After the sequencing process, sequences from pooled library are separated 
according to unique indices introduced during the sample preparation. The 
enrichment workflow of DNA demultiplexes the indexed reads, will generate a 
FASTQ files which is a text-based format containing both nucleotide sequence 
and its consistent quality scores. For each sample, reads with similar stretches of 
base calls are locally cluster. Forward and reverse reads were paired, which will 
create contiguous sequences. These contiguous sequences were aligned and 
mapped to the human genome reference by the Burrows-Wheeler Aligner (BWA) 
for variants identification. Variants will be identified, and the output files will be 
transcribed to the alignment folder by using the Genome Analysis Toolkit 
(GATK). This alignment folder is called variant call format file (VCF). These 
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steps will be directly performed by the MiSeq platform (MiSeq Reporter 2.5)[43]. 
All the following steps are a default setting in the MiSeq platform we used it as it 
is without changing any of the parameters. 
The VCF file contains an enormous amount of information needs 
filtration, using the specific pipeline that aid in doing this purpose. The pipeline 
that we used (hypothesized) depends on different parameters, quality of the 
sequencing coverage and target coverage, passing variants, allele frequency, and 
mutation type. For the quality of sequencing, we depend on the 20X (Q20) 
coverage as the depth of sequencing coverage with target coverage that ranges 
between (95.7% to 97.5%). Also we choose only the passing variants because we 
want to filter those passing variants to exclude the false positive.in order to end up 
with a list of most rare variants, we choose the allele frequency which is <1%. 
Moreover, to detect the mutation type, we depend on the pathological mutation 
only.  
These mutations have been checked by using different software such as 
SIFT (Sorting Intolerant From Tolerant); this database distinguishes the tolerant 
mutation form in tolerant one. The other website that used for detecting the 
severity of the mutations is PolyPhen-2 (Polymorphism Phenotyping v2). This 
website used as a tool for expecting the effect of changing in amino acid on the 
structure and function of the protein. The other software that we used is 
MutationAssessor that predict the influence of substation of amino acid in the 
function of the protein (Figure 4). 
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Figure 4. Pipeline of the hypothesized criteria. This pipeline containing filtering 
parameters that used in the filtering the data of VCF.  
 
 
This pipeline could be implemented on all kind of autistic conditions, and this 
appears clearly in which we depend on affected patients only who include the 
homozygous and heterozygous, on other word, the dominant, recessive, and de novo 
mutations. 
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3.3 Evaluation of Variants in the four patients: 
3.3.1 Primer design: 
After variant list generation according to the applied quality test criteria, 
we designed primers for the 18 variants that passing the hypothesized criteria and 
we chose 4 random variants that were failed by the hypothesized criteria while 
they passed according to MiSeq reporter criteria. Using UCSC genome 
bioinformatics did the designing of the primers and Primer 3 input (version 0.4.0) 
software. By using UCSC genome, we were able to find the human reference for 
each gene in order to use it in primer designing of the desired variants. We used 
(feb.2009 (GRCH37/hg19)) assembly, after we the gene name was entered; the 
proper isoform was chosen based on the (NM) number that provided by VCF for 
each variant, which distinguishes the isoforms of the same gene. Then the 
mRNA/Genomic alignment was checked to design the primer based on the 
sequence of the mRNA, then the sequence of the gene was taken and paste it into 
the Primer 3 software to pick up the suitable primers.  
The properties of the picked primers were checked by using Amplifix 
software, these properties including Tm (Melting Temperature), GC content, 3’end 
stability, polyX, self-dimer, and self-end dimer. All those properties must be 
optimized and checked well before choosing the primer; this will help in ensuring 
the efficiency of the primer work. For more confirmation of the quality of the 
picked primers, we check them by using tools in the UCSC genome such as in-
silico PCR, and BLAT search genome. These tools help us in confirming the 
specificity of the picked primers; that means, these primers could align only to the 
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desired gene on its chromosome and not with other regions, genes, or another 
chromosome. They run in-silico PCR and check all these properties. 
 
3.3.2 Optimization of the Primers: 
The designed primers had been ordered by using Integrated DNA 
Technologies (IDT), after receiving we started the optimization process to check 
the proper condition for using these primers with the patient’s samples. 
First of all, we checked the (23) pairs of primers on a control sample, by 
doing PCR with different temperature degree to check the best annealing 
temperature. We choose three different temperatures, which are (52°C, 58°C, and 
60°C), and do PCR reaction with 20ng/µl DNA concentration (Table 3). Due to 
high DNA concentration in almost all of the samples when they run on an agarose 
gel, we decided to repeat the same mentioned conditioned with changing the 
DNA concentration, by using 10ng/µl instead of 20ng/µl (Table 4) (Table 5). 
Then we did the PCR using the optimized temperature, which is (58°C) for the 23 
pairs of primers by using the same PCR condition for all reaction. (Table 6) All 
the ingredients are ready made except the dNTP, which we prepared it (Table 7). 
The taq polymerase enzyme used is HotStar (Qiagen), and the dNTPs set is PCR 
grade (Qiagen). 
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Table 3. PCR Ingredients and the concentrations with DNA concentration of 20ng/µl. 
Ingredients Concentration 1X 
Sterile distilled water  __ 17.2ml 
PCR Buffer 10 X 2.5ml 
dNTPs 10mM 2ml 
Forward Primer 10µM 0.5ml 
Reverse Primer 10µM 0.5ml 
Taq Polymerase (HotStar) 5000U/ml 0.3ml 
DNA Sample  20ng/µl 2µl 
Total volume per tube  25µl 
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Table 4. PCR Ingredients and the concentrations with DNA concentration of 10ng/µl. 
Ingredients Concentration 1X 
Sterile distilled water  __ 17.2ml 
PCR Buffer 10 X 2.5ml 
dNTPs 10mM 2ml 
Forward Primer 10µM 0.5ml 
Reverse Primer 10µM 0.5ml 
Taq Polymerase (HotStar) 5000U/ml 0.3ml 
DNA Sample  10ng/µl 2µl 
Total volume per tube  25µl 
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Table 5. PCR Condition that used for optimization of the primers. 
 
  
 
 
 
 
 
 
Table 6. Optimized Condition of PCR. This condition applied for the four patients to 
detect the correct variation. 
 
 
 
 
 
 
Step Temperatures Time  
1 95°C 15min  
2 94°C 60sec 
 
3 (52,58,60)°C 30sec 
4 72°C 60sec 
5 72°C 10min  
6 4°C ∞  
Step Temperatures Time   
1 95°C 15min  
2 94°C 60sec 
 
3 58°C 30sec 
4 72°C 60sec 
5 72°C 10min  
6 4°C ∞  
35 Cycles 
35 Cycles 
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Table7. dNTP preparation. It shows the concentrations that used for each dNTP 
preparation. 
 
 
 
 
 
 
 
 
3.4     Polymerase Chain Reaction of the four patient’s samples: 
Primers of the variants were optimized and checked for the proper 
condition of the PCR, then PCR for each patient with the detected variants 
was carried out by using annealing temperature of 58°C. 
 
 
 
 
Reagent Concentration 1X 
dATP 10 mM 2.5 µl 
dCTP 10 mM 2.5 µl 
dGTP 10 mM 2.5 µl 
dTTP 10 mM 2.5 µl 
Autoclaved distilled water ____ 90 µl 
Total volume per tube  100 µl 
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3.5 Gel Electrophoresis: 
The entire PCR product was checked by using (2% agarose gel) to detect 
desired bands at specific sites. 100 bp Plus Ladder (Gel Pilot Qiagen) was 
used as a ladder marker for the patient’s samples bands. 
 
3.6 Validation by Sanger Sequencing: 
Sanger sequencing was used for variants validation following checking the 
right size of the band of interest on the gel for the patient’s samples. Sanger 
sequencing plays an important role in variants validation that although the next 
generation sequencing is more useful in the long read fragment, but Sanger 
sequencing is more helpful for the small-scale projects and for validation of 
Next Generation sequencing results. First of all, mixture of 2.5µL of the PCR 
product in the Optical plate, 96 well ( Applied Biosystems Inc) and 1µl of 
3.2pmol of primer for each reaction in Fast Reaction plate, 96 well (Applied 
Biosystems Inc) was submitted to the Sanger sequencing laboratory for 
sequencing .  
After that, 1µl of ExoSAP-IT that stored at -20°C (USB/Affymetrix) will 
be added to 2.5µl of the submitted post-PCR reaction product to be a total of 
3.5μl reaction volume. ExoSAP-IT, aimed to do a fast and efficient 
purification of Polymerase Chain Reaction (PCR) products for downstream 
applications such as sequencing. It is made up of having two hydrolytic 
enzymes, Exonuclease I and Shrimp Alkaline Phosphatase (SAP), which is 
formulated in an specially optimized buffer aimed to the removal of unwanted 
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primers and dNTPs from a PCR product mixture. Then the plate was sealed 
with MicroAmp Optical Adhesive Film (Applied Biosystems). Which 
followed by Spinning down for 2 seconds, mixing by vortex for 2 seconds, 
then spinning down to collect the reaction mix in the bottom of the well. After 
that, the plate was put in the thermal cycler to start the purification step and 
the condition was used as follows in (Table 8). 
 
 
Table 8. Thermal cycler program that performed after addition of ExoSAP-IT to the 
post-PCR reaction product.  
Temperature Time (minutes) Remarks 
37°C 15  Hydrolysis of single-stranded DNA 
and dNTPS 
80°C 15  Inactivate the enzymes 
4°C ∞  
 
 
Once the reaction is done, the plate was briefly centrifuged to collect each 
sample at the bottom of its well. Then the plate Proceeded to Cycle Sequencing 
reaction, this step was done by transferring 2µl of purified sample to the 
submitted 1µl specific 3.2pmol reaction primer wells plate, and place 1µl of 
Control DNA template (pGEM-3Zf+(0.2 μg/μl)) in in the last reaction well of 
the plate run to be processed in parallel with samples. The DNA control 
template was added to 4µl of M13 Control Primer (0.8pmol). After that Ready 
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Reaction Mix (Applied Biosystem Inc.) and 5X Sequencing Buffer (Applied 
Biosystem) were added to the plate as follows; a total of 7µl of Master Mix is 
added to the sample and 5µl to the Control (M13). Then the plate had been 
sealed with MicroAmp Optical Adhesive Film. After that, it was spin down for 
2 seconds, mixed by vortex for 2 seconds, and spin down to collect the reaction 
mix in the bottom of the well (Table 9). After that, the plate was put in the 
thermal cycler (the Fast 9800 Thermal cycler) for doing the PCR to start the 
sequencing reaction (Table 10). When the reaction finished, the plate was spin 
done by using a centrifuge to ensure the total volume was in the bottom of the 
wells and not evaporated.  
 
 
Table 9. Master Mix reagent that added to the post-PCR reaction product. 
Reagents PCR Product M13 Control 
PCR grade distilled water 
(Millipore Filtration System) 
4µL 2µL 
5X Sequencing Buffer 1µL 1µL 
Ready Reaction Mix 2µL 2µL 
Total of Master Mix 7µL 5µL 
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Table 10. PCR condition that set in the Fast 9800 thermal cycler.  
Temperature Time Cycle 
96°C 1min 1 
96°C 10sec  
25  50°C 5sec 
60°C 75sec 
4°C ∞  
 
 
After the reaction had been done, it stopped by using a BigDye XTerminator 
Purification Kit (Applied Biosystem Inc) that composed of SAM solution and 
Xterminator solution. First of all, all the solution must be put in the room 
temperature before starting the reaction, then vortex them well to avoid any 
precipitation of crystals (if crystals observed in the SAM solution, it must be 
placed the SAM bottle in 37°C water bath for 10 minutes or till the crystals 
completely dissolved). For each reaction, the Dye-Terminator premix solution had 
been prepared by adding 45µL of SAM solution with 10µL of Xterminator solution 
and multiplied by the number of reactions to know the exact volume to prepare as a 
premix. After that, the premix had been placed on the shaker to keep solution 
homogenous and it must always agitate before each aspiration. 
55µl of premix was aspirated and loaded to each well at the plate. After 
adding to all wells on the plate, the plate had been sealed properly to avoid cross 
contamination with MicroAmp adhesive foil. The plate was put in the vortex 
machine for 30 minutes at 1800rpm to allow the reagent to be mixed properly with 
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the samples, and then it was centrifuged for 2 minutes at 2,800 rpm. Once the 
centrifuge step completed, 5µL of the supernatant of each well were transferred to 
a new optical plate, added to 10µL of HiDi (Applied Biosystem Inc.) for each 
reaction sample. Then the plate was covered with septa. After that, the plate had 
been mixed well by using a vortex, and then it was spin down by using centrifuge 
for 20 seconds. For Assembling the plate for loading in the sequencing machine, 
the plate was placed into the plate base, and checking that the holes of the plate 
retainer and the septa strips are aligned, if not, the plate was reassembled. Then the 
plate was ready for putting into the sequencing machine. The Sanger sequencing 
machine that was used: ABI 3130XL, and 3730XL Genetic Analyzers. 
 
3.7 Calculation: 
(Sock Concentration X volume) before =  (concentration X volume) after 
 Needed volume = ( ௖௢௡௖௘௡௧௥௔௧௜௢௡ ௑ ௩௢௟௨௠௘)௔௙௧௘௥ୗ୭ୡ୩ େ୭୬ୡୣ୬୲୰ୟ୲୧୭୬  
                          = ଶ.ହ ௑ ଵ଴ଵ଴  
               =2.5 
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3.8 List of Materials: 
NO Materials Manufacturer 
 
Storage 
Temperature 
Catalogue 
number 
A MiSeq NGS 
Materials: 
 
   
A.1 Flow Cell  Illumina 2°C to 8°C RH-102-1001 
A.2 Optical plate, 96 well Applied 
Biosystems Inc 
Room 
temperature 
N8010560 
A.3 Fast Reaction plate, 96 
well 
Applied 
Biosystems Inc 
Room 
temperature 
4346907 
B PCR Material:    
B.1 Optical Adhesive Covers Applied 
Biosystems Inc 
Room 
temperature 
4311971 
B.2 MicroAmp Clear Adhesive 
Films 
Applied 
Biosystems Inc 
Room 
temperature 
4306311 
B.3 Optical plate, 96 well Applied 
Biosystems Inc 
Room 
temperature 
N8010560 
B.4 Fast Reaction plate, 96 
well 
Applied 
Biosystems Inc 
Room 
temperature 
4346907 
C Agarose Gel 
Electrophoresis 
Material 
   
C.1 Mini-Sub® Cell GT 
Horizontal Electrophoresis 
System, 7 x 7 cm tray, 
with casting gates 
Bio-Rad Room 
temperature 
1704406 
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D 
 
 
Sanger Sequencing 
Material: 
D.1 Optical Adhesive Covers Applied 
Biosystems Inc 
Room 
temperature 
4311971 
D.2 MicroAmp Clear Adhesive 
Films 
Applied 
Biosystems Inc 
Room 
temperature 
4306311 
D.3 Optical plate, 96 well Applied 
Biosystems Inc 
Room 
temperature 
N8010560 
D.4 Fast Reaction plate, 96 
well 
Applied 
Biosystems Inc 
Room 
temperature 
4346907 
D.5 Plate septa, 96 well Applied 
Biosystems Inc 
Room 
temperature 
0410065073 
C.6 Plate base, 96 well 3130xl Applied 
Biosystems Inc 
Room 
temperature 
4317237 
D.7 Plate base, 96 well 3730xl Applied 
Biosystems Inc 
Room 
temperature 
4334873 
D.8 Plate retainer, 96 well 
3130xl 
Applied 
Biosystems Inc 
Room 
temperature 
4317241 
D.9 Plate retainer, 96 well 
3730xl 
Applied 
Biosystems Inc 
Room 
temperature 
4334868 
D.10 MicroAmp 8-Cap Strip Applied 
Biosystems Inc 
Room 
temperature 
N801-0535 
D.11 MicroAmp Fast Reaction 
Tubes 
Applied 
Biosystems Inc 
Room 
temperature 
4358293 
D.12 MicroAmp 8-Tube Strip 
(0.2mL) 
Applied 
Biosystems Inc 
Room 
temperature 
N8010580 
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3.9 List of Reagents: 
 
NO Reagent and Kits Manufacturer 
 
Storage 
Temperature 
Catalogue 
number 
A MiSeq NGS Reagents 
and Kits 
   
A.1 TruSight Rapid Capture kit 
(48 samples) 
Illumina 2°C to 8°C FC-140-1104 
A.2 Nextera Rapid Capture 
Custom Enrichment Kit (96 
Samples) 
Illumina -15°C to -25°C FC-140-1008  
 
A.3 Trusight Rapid Capture 
sample preparation kit 
Illumina Room 
temperature 
FC-
1409003DOC 
A.4 AMPure XP Beads Beckman Coulter 2°C to 8°C A63880 
A.5 2N NaOH Illumina -15°C to -25°C SS264-1 
A.6 MiSeq Reagent Kit v3, 150 
Cycles, Box1 and Box 2 
Illumina Box1: -15°C to -
25°C. 
Box2: 2°C to 8°C  
MS-102-3001 
A.7 Ethanol EMSURE Room 
Temperature 
K43504883223 
A.8 TruSight Autism sequencing 
panel 
Illumina 2°C to 8°C FC-121-0203 
A.9 TruSeq Dual Index 
Sequencing Primer Box, 
Single Read  
Illumina 15°C to 30°C FC-121-1003 
 
B 
 
PCR Reagents and 
Kits 
   
B.1 PCR grade distilled water Roche Room 
temperature 
03315932001 
B.2 dNTPs set (PCR grade) Qiagen -20°C 201912 
B.3 taq polymerase enzyme 
(Hotstar) 
Qiagen -20°C 145041263 
C Agarose Gel Reagents    
C.1 UltraPure10x TBE Buffer Gibco by life 
technologies 
Room 
Temperature 
15581-044 
C.2 Agarose powder Research Products 
International 
Corp. 
Room 
temperature 
9012-36-6 
C.3 Ethidium Bromide Gene Choice Room 
temperature 
5450 
C.4 5x loading Dye, Gel Pilot Qiagen 4 °C 142346877 
C.5 100bp Plus Ladder, Gel Pilot Qiagen 4 °C 19.4 
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D  
Sanger Sequencing 
Reagents and kits 
D.1 M13 Template (pGM3Zf 
(+)) 
Applied 
Biosystem Inc. 
-20°C 1307127 
D.2 M13 Primer Applied 
Biosystem Inc. 
-20°C 182871673 
D.3 Hi-Di formamide Applied 
Biosystem Inc. 
-20°C 1508392 
 
D.4 
 
BigDye XTerminator 
Purification Kit 
 
Applied 
Biosystem Inc. 
 
4°C 
 
1509095 
D.5 SAM solution Applied 
Biosystem Inc. 
4°C 509095 
D.6 ExoSAP-IT (ExoSAP-IT™) USB/Affymetrix 
 
-20°C 4227968 
D.7 BigDye Terminator v3.1 
Cycle Sequencing Kit 
Applied 
Biosystem Inc. 
-20°C 4336943 
D.8 Genetic Analyzer 10X 
Running Buffer with EDTA 
Applied 
Biosystem Inc. 
4°C 1506252 
D.9 Polymer 
POP-7™ 3130 xl 
POP-7™ 3730 xl 
Applied 
Biosystem Inc. 
4°C  
4352759 
4363929 
D.10 Ready Reaction Mix Applied 
Biosystem Inc. 
-20°C 1309144 
D.11 Sequencing Buffer (5X) Applied 
Biosystem Inc. 
4°C 1004119 
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3.10 List of Primers: 
NO Primer Name Manufacturer 
 
Storage 
Temperature 
Reference 
number 
1 FMR1_17F IDT Room 
temperature 
70016950 
2 FMR1_17R IDT Room 
temperature 
70016951 
3 RAI1_3F IDT Room 
temperature 
70016952 
4 RAI1_3R IDT Room 
temperature 
70016953 
5 ZNF804A_4F IDT Room 
temperature 
70016954 
6 ZNF804A_4R IDT Room 
temperature 
70016955 
7 CHD7_2F IDT Room 
temperature 
70016956 
8 CHD7_2R IDT Room 
temperature 
70016957 
9 RELN_25GF IDT Room 
temperature 
70016958 
10 RELN_25GR IDT Room 
temperature 
70016959 
11 PCDH9 _2F IDT Room 
temperature 
70016960 
12 PCDH9 _2R IDT Room 
temperature 
70016961 
13 EHMT1_5F  IDT Room 
temperature 
70016962 
14 EHMT1_5R  IDT Room 
temperature 
70016963 
15 Dmd_17R IDT Room 
temperature 
70016964 
16 Dmd_17F IDT Room 
temperature 
70016965 
17 MET_16F IDT Room 
temperature 
70016966 
18 MET_16R IDT Room 
temperature 
70016967 
19 Tsc2_41-42F IDT Room 
temperature 
70016968 
20 Tsc2_41-42R IDT Room 
temperature 
70016969 
21 ANKRD11_9F IDT Room 
temperature 
70016970 
22 ANKRD11_9R IDT Room 
temperature 
70016971 
23 CREBBP_31R IDT Room 
temperature 
70016972 
24 CREBBP_31F IDT Room 
temperature 
70016973 
25 SHANK2_10F IDT Room 
temperature 
70016974 
26 SHANK2_10R IDT Room 
temperature 
70016975 
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27 AUTS2_19F IDT Room 
temperature 
70016976 
28 AUTS2_19R IDT Room 
temperature 
70016977 
29 RELN_13F IDT Room 
temperature 
70016978 
30 RELN_13R IDT Room 
temperature 
70016979 
31 LAMC3_8F IDT Room 
temperature 
70016980 
32 LAMC4_8R IDT Room 
temperature 
70016981 
33 CHD7_2F* IDT Room 
temperature 
70016982 
34 CHD7_2R* IDT Room 
temperature 
70016983 
35 SHANK2-3F IDT Room 
temperature 
70016984 
36 SHANK2-3R IDT Room 
temperature 
70016985 
37 CDKL5_12F IDT Room 
temperature 
70312521 
38 CDKL5_12R IDT Room 
temperature 
70312522 
39 AUTS2_8F IDT Room 
temperature 
70312523 
40 AUTS2_8R IDT Room 
temperature 
70312524 
41 PON3_9F IDT Room 
temperature 
70312525 
42 PON3_9R IDT Room 
temperature 
70312526 
43 KIRREL3_3F IDT Room 
temperature 
70312527 
44 KIRREL3_3R IDT Room 
temperature 
70312528 
45 ATRX_8F IDT Room 
temperature 
70312529 
46 ATRX_8R IDT Room 
temperature 
70312530 
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4. Results: 
4.1  Analysis of the four patients: 
Four ASD patients have been analyzed by using MiSeq platform according to 
the pipeline that have been described before, and result in having enrichment 
report for each sample as well as VCF file. The enrichment report containing all 
details related to the quality of the data released from the MiSeq and the coverage 
depth. We depend on the 20X coverage with assembly range of (95.7-97.5%) 
among the four patients. Within 20X coverage, we compare the four patients in 
the case of targeted bases covered at depth, total targeted based covered, and the 
target coverage. For the number of targeted bases covered at depth, it was (911, 
580, 332, and 437) respectively among the four patients. While the Total targeted 
based covered for each patient it was as follows respectively (316061, 320822, 
322027, and 320756). The target coverage for the patients was as follows: 95.7% 
for the first patient, 97.1% for the second patient, 97.5% for the third patient, and 
97.1% for the fourth patient (Table 11). 
In addition, we compared between the four patients in the level of the targeted 
fragment. The fragment length median varies among the patients as follows: 
242bp, 196bp, 226bp, and 208bp respectively. The minimum and the maximum 
length of the targeted fragment in each patient were as follows: (95bp, 714bp) for 
the first patient, (55bp, 494bp) for the second patient, (83bp, 641bp) for the third 
patient, and (74bp, 563bp) for the fourth patient. Moreover, the enrichment report 
calculated the Standard deviation for each patient, 95, 60, 83, and 69 respectively 
for the patients (Table 12). 
  
 42 
Table 11. Comparison among the four patients in the coverage of the variants. 
Patients Depth of 
sequencing 
coverage 
Number of 
targeted bases 
covered at 
depth 
Total targeted 
based covered 
Target 
coverage 
Patient #1 20X 911 316,061 95.7% 
Patient #2 20X 580  320,822 97.1% 
Patient #3 20X 332  322,027 97.5% 
Patient #4 20X 437  320,756 97.1% 
 
 
Table12. Comparison between the four patients in the targeted fragment length, 
minimum, maximum and standard deviation. 
Patients Fragment 
Length Median 
Minimum Maximum Standard 
deviation 
 
Patient #1 242 bp 95 bp 714 bp 95 bp 
Patient #2 196 bp  55 bp 494 bp 60 bp 
Patient #3 226 bp  83 bp 641 bp 83 bp 
Patient #4 208 bp  74 bp 563 bp 69 bp 
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4.2 Applying the hypothesized pipeline: 
For each patient, there is a list of passing and failing variants according to the 
MiSeq reporter criteria in the VCF. The hypothesized filtering method was applied to 
the passing variants (high quality variants) of the VCF for the each patient in order to 
be able to identify the variants. After using the hypothesized filtering criteria, the 
number of passing variants reduced dramatically in each patient as follows: in the first 
patient, the number of passing variants was 100 variants, while after filtering it 
become 5 variants only. The passing variants encountered in the second patient were 
83 variants that become 4 variants after filtering. For the third patient, it was 110 then 
after filtering became 4 variants, while the number of passing variants for the last 
patient was 108 variants, which become 5 variants after filtering (Table 13). The list 
of passing variants in each patient are as follows: (FMR1, RAI1, ZNF804A, CHD7, 
CREBBP) in patients #1, (RELN-25e, CHD7*, SHANK2, and PCDH9) in patient #2, 
(TSC2, DMD, MET, SHANK 2-3e) in patient#3, and (AUTS2, RELN-13e, LAMC3, 
ANKRD11, and EHMT1) in patient #4. (Table 14,Table15, Table 16, Table 17). For 
the variants that was chosen randomly among the 4 patients which failed based on the 
hypothesized criteria while passed based on the MiSeq criteria (low quality variants), 
were (CDKL5, and AUTS2 in patient #1, PON3 in patient #2, KIRREL3 in patient 
#3,and ATRX, in patient #4) (Table 18). 
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Table 13. Comparison among the four patients in the pass and fail mutation before 
and after filtering. 
 
 
Table 14. List of passing variants of the patient #1. The list explains the 
chromosomes, type of variant, genotyping, and the allele frequency. 
Genes Variant Chromosome Type Genotype Allele 
Frequency 
FMR1 c.*746T>C X snv Homozygous 0.18 
RAI1 c.840delG 17 Deletion Heterozygous 0 
ZNF804A c.2088_2089insACA 2 Insertion Heterozygous 0 
CHD7 c.389A>G 8 snv Heterozygous 0 
CREBBP c.6542A>G 16 snv Heterozygous 0 
 
Patients No# of 
mutated genes 
before filtering 
Pass variants  Fail variants No# of passing 
mutated genes 
after filtering 
Fail variants 
after filtering 
Patient #1 121 100 21 5 95 
Patient #2 93 83 10 4 79 
Patient #3 122 110 12 4 106 
Patient #4 129 108 11 5 103 
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Table 15. List of passing variants of the patient #2. The list explains the 
chromosomes, type of variant, genotyping, and the allele frequency. 
Genes Variant Chromosome Type Genotype Allele 
Frequency 
RELN-25e c.3477C>A 7 snv Heterozygous 0.14 
PCDH9 c.2866G>C 13 snv Homozygous 0 
CHD7* c.127A>G 8 snv Heterozygous 0 
SHANK2 c.2397_2402dupGCCATT 11 Insertion Heterozygous 0 
 
 
Table 16. List of passing variants of the patient #3. The list explains the 
chromosomes, type of variant, genotyping, and the allele frequency. 
Genes Variant Chromosome Type Genotype Allele 
Frequency 
TSC2 c.5389A>T 16 snv Heterozygous 0 
SHANK2_3e c.332 G>A 11 snv Heterozygous 0 
DMD c.2143A>T X snv Homozygous 0.36 
MET c.3497G>T 7 snv Heterozygous 0 
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Table 17. List of passing variants of the patient #4. The list explains the 
chromosomes, type of variant, genotyping, and the allele frequency. 
Genes Variant Chromosome Type Genotype Allele 
Frequency 
AUTS2 c.3374_3375insCCACCA 7 Insertion Heterozygous 0 
RELN_13e c.1483A>G 7 snv Heterozygous 0 
LAMC3 c.1414C>A 9 snv Heterozygous 0 
EHMT1 c.905A>G 9 snv Heterozygous 0 
ANKRD11 c.1130C>T 16 snv Heterozygous 0 
 
 
Table 18. Low quality list of variants in all patients that were chosen randomly. 
Patients Genes Variant Chromosome Type Genotype 
Patient# 1 AUTS2 c.1343T>C 7 snv Heterozygous 
CDKL5 c.1324C>A X snv Heterozygous 
Patient# 2 PON3 c.939G>T 7 snv Heterozygous 
Patient# 3 KIRREL3 c.263G>T 11 snv Heterozygous 
Patient# 4 ATRX_8 c.957G>T X snv Heterozygous 
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4.3 The effect of the hypothesized filtering criteria: 
The effect of hypothesized filtering criteria shown clearly in reducing the 
number of passing variants that needs validation by Sanger sequencing. This will 
lead to decrease the error rate and help in distinguishing the real variants from 
false positive and/or false negative (Figure 5).  
 
 
 
 
 
 
 
Figure 5. Variants that resulted before and after filtering criteria. It shows the effect of 
filtering criteria, which reduce the number of the passing variants significantly. (100 
passing variants become 5 for patient#1, 83 passing variants become 6 after filtering 
for patients #2, 110 passing variants become 4 after filtering for patient#3, and 108 
passing variants become 6 after filtering for patient#4). 
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After filtering we end up with a total of 18 variants among the four patients (5 
variants in the first patient, 4 variants in the second patient, 4 variants in the third 
patient, and 5 variants in the fourth patient). 
 
4.4 Evaluation of Variants in the four patients: 
4.4.1 Primer Design: 
Once the primers had been designed, 2 lists of variant primers were created. The 
first list includes the high quality variants (Table 19) and the second list includes the 
low quality variants (Table 20). Each list includes some properties such as: the primer 
name, the sequence of each primer, product size, Tm, and primer length. 
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Table 19. Primers list for the high quality variants among the 4 patients. 
Primer Name 
(gene_exon_amplic
on) 
Primer Sequence TM 
(°C) 
Length 
(bp) 
Product 
size 
(bp) 
FMR1_17F TGTAGCAAACCCTGTCAAAC 52 20 218 
FMR1_17R GCCTCTCTCAGATGAAGATAGTT 53 23 
RAI1_3F CTCAGCATTCCCAGTCCTTC 54 20 496 
RAI1_3R TGCTGGCTGTAGGGAAAGTT 55 20 
ZNF804A_4F AAAGGCCCAAATCAGAATCC 52 20 447 
ZNF804A_4R TGCAGGGAGCAACTGAAGTA 55 20 
CHD7_2F CCGAACAGAATGATGAGCAA 52 20 440 
CHD7_2R GGTCCTGAGGTGGCAATAAA 54 20 
RELN_25GF ggacgagaccatttccacat 54 20 633 
RELN_25GR cctgcaaatgggaaaatgag 51 20 
PCDH9 _2F CCTGGCCAAGCACTACAAAT 55 20 190 
PCDH9 _2R ACTGCACTCTGAGGCACTGA 57 20 
EHMT1_5F  ggtttgctggtgattttggt 53 20 423 
EHMT1_5R  acgaacactctgcccctatg 56 20 
Dmd_17R CCACCACTCAGCCATCACTA 55 20 232 
Dmd_17F caccaccaacaaaactgct 53 19 
MET_16F ggtggcatcattcactcaga 54 20 646 
MET_16R gtgcacagtttctggcacat 56 20 
Tsc2_41-42F CCCTGCACGCAAATGTGA 55 18 788 
Tsc2_41-42R tggaggaaggtgactgtgtg 55 20 
ANKRD11_9F AAGAACCCAGAGCCACAGAA 55 20 343 
ANKRD11_9R TGGCATTAGAAGGCTCTCGT 55 20 
CREBBP_31R AGCCTGCAGAACCTGAATG 54 19 295 
CREBBP_31F CTTGAGGCTGCTGGAACTG 55 19 
SHANK2_10F TGCAGGAAGAGGACGAGAAG 56 20 384 
SHANK2_10R GTTGGCTGGAGTTCAACGAAG 56 21 
AUTS2_19F GATCCTTACCGAGAACTTGACATT 55 24 409 
AUTS2_19R GAGGGGTCTTGTTGAGGAGT 55 20 
RELN_13F aatagctactttggccttcac 53 21 553 
RELN_13R tcactcttccttcctgataactc 53 23 
LAMC3_8F ctgtggtaatgtcagatgtca 52 21 687 
LAMC4_8R ctgaatccccagtgtttagac 53 21 
CHD7_2F* TGAAGTGAAGCACAGGCAA 54 19 642 
CHD7_2R* GCCATATAGCTGCCCATCTG 54 20 
SHANK2-3F gcgtcctctgtcactcatca 56 20 250 
SHANK2-3R tacCTCCAGGGAAGGAAC 51 18 
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Table 20. Primers list for the low quality variants among the 4 patients. 
Primer Name 
(gene_exon_ampl
icon) 
Primer Sequence TM 
(°C) 
Length  
(bp) 
product size 
(bp) 
CDKL5_12F CCACACCTTCTTAGCCCAAA 20 54 195 
CDKL5_12R ATGCCGACTCTGCTTTTCA 19 54 
AUTS2_8F gatagCAGCAGCAGAAGCAG 20 55 229 
AUTS2_8R CCACCTGCAGACTTCCTGAT 20 55 
PON3_9F gaatgtttgggaaggacatca 21 52 210 
PON3_9R TGTGAAATACGGTGCCTATGA 21 53 
KIRREL3_3F CAGCCAGTGACGCTACTTTG 20 55 168 
KIRREL3_3R ctaggaaggtggatgggt 18 51 
ATRX_8F GAACAGTTGTTGCAGCAAA 19 51 233 
ATRX_8R TTGGCTGTGGTCTCAATCA 19 53 
 
 
4.4.2 Results of Primers optimization: 
After receiving the primers, we did optimization of them by using different 
temperature degree in order to see the best condition to run the PCR for the patient, 
which will be proceeded to Sanger sequencing. The optimization condition was done 
on the temperatures degrees (52°C, 58°C, and 60°C) with 20ng/ml DNA (Figure 6). 
We choose these specific temperatures because they are the recommended 
temperatures that were given by the Amplifix software that was used when designing 
the primers. All the prepared primers lay within this range. After doing the first 
optimizing PCR, we found lots of non-specific binding bands, and this could be due to 
high concentration of the DNA template added. Because of that we reduced the 
concentration of the DNA to the half (10ng/ml) of its original concentration and 
repeat the PCR with the same mentioned condition except the concentration of the 
DNA that was reduced (Figure 7). 
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After that we choose the 58°C as the recommended annealing temperature in 
PCR that gave the band of the gene of interest shown and repeat the picture for the 23 
genes (18 variants and 5 variants) (Figure 8). Once the optimized condition has been 
done, PCR had been done on the four patients and a normal control sample by using 
the previous optimized condition for each variant detected in each patient (Figure 9). 
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Figure 6.  Agarose gel electrophoresis of PCR product represent the optimization of the variant’s 
primers using 20ng/µl DNA concentration with gradient temperatures degrees (52°C, 58°C, and 60°C) 
respectively starting from the DNA ladder (M), GelPilot 100bp Plus Ladder (100-1500 bp) had been 
used as a DNA ladder, each 3 lanes represent one variant. a. PCR product of optimized condition of 
high quality variants among the 4 patients. b. PCR product of the optimized condition of low quality 
variants among the 4 patients. 
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b. 
 
 
 
Figure 7.  Agarose gel electrophoresis of PCR product represent the optimization of the variant’s 
primers using 10ng/µl DNA concentration with gradient temperature degrees (52°C, 58°C, and 60°C) 
respectively starting from the DNA ladder (M), GelPilot 100bp Plus Ladder (100-1500 bp) had been 
used as a DNA ladder, each 3 lanes represent one variant. a. PCR product of optimized condition of 
high quality variants among the 4 patients. b. PCR product of the optimized condition of low quality 
variants among the 4 patients. 
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 b. 
 
 
 
 
Figure 8.  Agarose gel electrophoresis of PCR product represent the optimized condition of the 
variant’s primers using 10ng/µl DNA concentration with temperature degree 58°C. (M) Represent 
DNA ladder GelPilot 100bp Plus Ladder (100-1500 bp), and each lanes represent one variant. a. PCR 
product of optimized condition of high quality variants among the 4 patients. b. PCR product of the 
optimized condition of low quality variants among the 4 patients. 
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e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Agarose gel electrophoresis of PCR product represent the variant’s detected among the 4 
patients using 10ng/µl DNA concentration with temperature degree 58°C. (M) Represent DNA ladder 
GelPilot 100bp Plus Ladder (100-1500 bp), and each lanes represent one variant. a. PCR product for 
the variants that detected in patient #1. b. PCR product for the variants that detected in patient #2.c. 
PCR product for the variants that detected in patient #3. d. PCR product for the variants that detected in 
patient #4.e. PCR product for the variants in the normal control sample.  
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4.5 Identification of SNVs and In-dels in each patient: 
After applying the hypothesized pipeline, we end up with a list of SNVs and 
In-dels in each patient. Patient#1 had 3 SNVs (point mutation) in (FMR1, CHD7, and 
CERBBP) and 2 In-dels (Insertion) in (ZNF804A, and RAI1), while there are 3 SNVs 
(point mutation ) in (RELN-25e, PCDH9, and CHD*) and 1 In-del (SHANK2) 
detected in  patient #2 .in patient #3 and #4 there was no any In-dels detected, on the 
other hand , all the variants that were detected was SNVs (point mutation ) that are 
present  as follows; (MET, Dmd, Tsc2, and SHANK2-3) in patient #3, and (RELN-
13e, LAMC3, EHMT1, and ANKRD11) in patient #4 .(Figure 10) 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Chart that shows the numbers and types (SNVs or In-dels) of the variants 
that were detected after applying the hypothesized criteria on the four patients. Patient 
#1 (3 SNV and 2 In-Dels), patient #2(3 SNV and 1 In-Del), patient #3 (4 SNV), and  
patient #4 (4 SNV). 
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4.6 Validation by Sanger sequencing: 
Once the condition has been optimized for the primers detecting the variants 
calls, Sanger sequencing analysis had been used in order to validate the presence or 
absence of the variants according to the hypothesized criteria.  
Each patient had a list of variants that had been processed by Sanger 
sequencing, some variants could not be sequenced due to some sequencing problems, 
while most of them were validated. For validation, a control sample was sequenced to 
be used as a reference in population along with the reference used by the software 
(UCSU genome browser) for more conformational analysis. Although Forward and 
reverse primers for each variant were employed in the sequencing to give high chance 
of detection and conformation of the presence or absence of the variation that had 
been called, one direction was used as a detection method for alignment to the 
reference and control sample. 
 The list of variants that had been generated after doing the sequencing for the 
first patient was (FMR1, RAI1, ZNF804A, CREBBP, and CHD7) as the high quality 
variant while (CDKL5) was the only variant that had been sequenced as the low 
quality variant (Figure 11). (CHD7*, PCDH9, RELN-25e, and SHANK2) sequencing 
analysis was generated for the second patient as the high quality variant, and (PON3) 
as the low quality variant (Figure 12).  For the third patient, (Tsc2, Dmd, SHANK2-3, 
and MET) were generated as the high quality variant, on the other hand, (KIRREL3) 
was sequenced as low quality variant (Figure 13). The variants that were analyzed by 
Sanger sequencing for the fourth patient were (RELN-13e, LAMC3, EHMT1, and 
ANKRD11) as high quality variants, while (ATRX_8) was analyzed as low quality 
variant (Figure 14). So, (AUTS2, and AUTS2_8) were excluded from patient #4, 
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patient# 1 respectively because we did not get the correct sequence. 
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c.  
 
Figure 11. Chromatogram pattering of the variants called in patient #1 done through Sanger sequencing 
aligned with reference of each variant taken from (UCSC genome browser) and a one direction 
(forward or reverse) normal control sample. a. Chromatogram pattern for the variant called as high 
quality with point mutation (FMR1, CHD7, and CREBBP) respectively. b. Chromatogram pattern for 
the variant called as high quality with in-dels (insertion or deletion)(RAI1, and ZNF804A) respectively. 
c. Chromatogram pattern for the variant called as low quality without mutation (normal) (CDKL5). 
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Figure 12. Chromatogram pattering of the variants called in patient #2 done through Sanger sequencing 
aligned with reference of each variant taken from (UCSC genome browser) and a one direction 
(forward or reverse) normal control sample. a. Chromatogram pattern for the variant called as high 
quality with point mutation (RELN-25e, CHD7*, and PCDH5) respectively. b. Chromatogram pattern 
for the variant called as high quality with in-dels (insertion or deletion)(SHANK2). c. Chromatogram 
pattern for the variant called as low quality without mutation (normal) (PON3). 
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Figure 13. Chromatogram pattering of the variants called in patient #3 done through Sanger sequencing 
aligned with reference of each variant taken from (UCSC genome browser) and a one direction 
(forward or reverse) normal control sample. a. Chromatogram pattern for the variant called as high 
quality with point mutation (MET, Dmd, Tsc2, and SHANK2-3) respectively. b. Chromatogram pattern 
for the variant called as low quality without mutation (normal) (KIRRELE3). 
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Figure 14. Chromatogram pattering of the variants called in patient #4 done through Sanger sequencing 
aligned with reference of each variant taken from (UCSC genome browser) and a one direction 
(forward or reverse) normal control sample. a. Chromatogram pattern for the variant called as high 
quality with point mutation (RELN-13e, LAMC3, EHMT1, and ANKRD11) respectively. b. 
Chromatogram pattern for the variant called as low quality without mutation (normal)(ATRX_8). 
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5. Discussion: 
DNA Sequencing techniques are the key tools promoting new discoveries in 
many fields. These techniques have large benefits in different sciences (genetics, 
biotechnology, molecular biology, forensic sciences, and others) (Lilian et al., 
2002)[44]. The importance of using DNA sequencing methods is clearly established 
in some genetic diseases; that cannot be clinically identified, or when there is no 
correlation between the used test-result for specific genes detection and the known 
associated genes of some genetic diseases. In addition, they are very useful in the case 
of disorders that are genetically heterogeneous, which reflect the cases of more than 
100 genes [45]. Relative to the public health and safety, DNA sequencing methods 
showed chronological development. 
Recently, Next generation sequencing (NGS) is developed worldwide as a 
routine diagnostic method that is used in some diseases like cancer to detect some 
markers like BRAC1/2[46]. First, it is used for sequencing high throughput data 
makes great revolution in the field of biomedical researches and genetic diagnostic 
fields. The second significant advantage of NGS appears significantly in the cost. The 
cost of running samples by using next generation platforms like MiSeq depends on 
the number of samples that are pooled in one run. Nowadays, the scientists reach to 
the point with MiSeq platform is that it could reduce the cost of sequencing to 10 
folds in comparison with Sanger sequencing if we try to sequence up to 10000 
amplicons per one run[45]. 
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All of these advantages open the window of trying to find a proper way to use 
that magnificent machine and to get the maximum benefit from it. However, due to 
the sequencing of large genomes and the vast amount of data (that are generated by 
alignment of the short reads with their references) [47] , there is a high probability of 
producing false positive and false negative results and it become difficult to 
distinguish these from the true variants detected. Because of that, we try to develop a 
criteria that could help in this purpose by reducing the rate of false positive/negative 
and at the same time, this can help the researchers to get the benefit from the huge 
amount of the derived data, and manipulate these data for identifying the correct 
variants that are already diffuse in many biomedical research fields that the researcher 
is interested in. 
In this research, we used one of the great vital platforms of NGS which is 
MiSeq platform that is known to be faster, cost-efficient, give higher resolution, and 
has easier workflow when compared with other platforms of NGS [48]. 
Using Sanger sequencing method (the gold standard method) will not be time 
and cost effective in generating this huge amount of data, but it could help in 
validating the variants detected by next generation sequencing because although it is 
more accurate in detecting single variant in a single exome, but it is very costly 
ineffective and take longer time if it is used to sequence the whole genome for many 
patient or different exons in a single patient. So overlapping the two methods will be 
more efficient specifically in the diagnosis of a disease or in the research that conduct 
genetic diseases and need sequencing as a major method in their research. 
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However, there were lots of challenges that scientists face. The major 
challenge is the presence of false positive/negative and the difficulty in distinguishing 
them from real variant. In this research, we depended particularly on the Q20 as 
minimum quality coverage accepted at 20X (Qscore) that reflect the probability of 
having error base call with the accuracy of sequencing coverage that range between 
(97.5%-95.7%) among the four patients, we chosen this specific Qscore based on the 
enrichment MiSeq report that we have for the four patient and to cover as much as we 
could of correct variant calls.  
The obtained data results in our study are consistent with the results previously 
reported by Pagi et al., 2016 that shows consistency with the use of Q20 as minimum 
acceptance coverage in the criteria that used for filtering the data [49]. However,  in 
their case they used 2 Bioinformatics pipelines and made a comparison between them, 
the 2 Bioinformatics pipelines were: SeqNext and MiSeq Reporter to compare the 
coverage values between both of them. 
Although our study was consistencey with Pagi et al. studies in the target 
coverage, it showed inconsistency with the data that was published by Diociaiuti et 
al., 2016 [50]. In their defense Diociaiuti et al. used the Q30 as a minimum coverage 
(Qscore), because they mentioned that they had accuracy reads with 99.9% for all 
variants that are >30, but they chosen this criterion regardless of the number of 
variants that might be missed when using Q30. Because of that we took the broader 
range (Q20). 
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A cohort of 4 ASD patients was studied in this research by using a NGS 
approach from the Illumina MiSeq platform. The DNA library preparation was done 
by using TruSight Autism Panel illumina Kit and completed in two working days. 
After that, the samples were run on the MiSeq. MiSeqReporter, AV and IGV2.3 
software were used for interpretation of the result. A hypothesized filtering pipeline 
was used for filtering the data resulted from the MiSeqReporter and displayed as VCF 
file. This hypothesized filtering criteria depends on many categories to be considered 
when doing the filtering based on Q20 (20X), passing variants, allele frequency <1%, 
and mutation type (choosing the pathogenic mutations only). Each of these parameters 
was been chosen for specific reason. Q20 was used because it gave good quality as 
over all depth coverage which range between (95.7% and 97.5%). In addition, to 
avoid the false negative where some variants were missed when we applied the Q30 
(data not shown) after Sanger sequencing validation.  
Passing variants depends on sample type, and sample quality. Therefore, 
choosing passing variants done because it is suggested that highly confident variants 
will be in the passing part, however, less variants will be encountered as false 
negatives at the same time. Moreover, this assumption is supported by the data 
reported by Huilei et al., 2014 [51], they used the passing variants to be analyzed that 
are post-calling filters. The second reason for not using the not passing variants is due 
to the limited time of our study, therefore we can do it as a future work.  
Minor allele frequency was chosen to be <1%, the thresholds differs from one 
study to another, because most of the rare variants present in the population with the 
percentage of <1% [52] and this is consistent with the study done by Frazer et al., 
2009 they mentioned that the solid frequency boundary for a rare variant one of less 
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than 1% , and in addition we want to have larger number of variants to be validated in 
order to support our hypothesized pipeline [53]. However, some recent studies like the 
study done by Alkes et al., 2010, stated that there could be less than this percentage, 
for example they found that between 0.5% and 2% allele frequency. Also there were 
about one-eighth of genes could affect the trait and has at least one working allele 
despite depending on the property of the selected strength [54]. Other study used the 
0.5% as threshold cutoff like the work done by Tennessen et al., 2012 [55].  For 
mutation type, we choose only the pathogenic mutation because we were concerned 
of the mutations that result in alteration in the DNA level or even the protein level, 
this can open the door for further studies like molecular characterization of the newly 
identified mutated gene, in addition, investigate the affect of mutation in its 
corresponding protein structure, function and protein –protein interaction for better 
understanding of its pathophysiologic role in the developed disease which is our plan 
for the future study.  
 We used Sanger Sequencing to validate the filtered variants. A total of 23 
variants with different sizes resulted from the 4 patients after applying the filtering 
criteria, we found that, Sanger sequencing validated 21 of them was validated by 
Sanger sequencing and the remaining 2 (AUTS2, and AUTS2-8) were excluded from 
the study. 
The resulted in 21 variants not all related to the same variant type; they 
include SNVs and In-dels (short Insertion and Deletion). Patient#1 showed 3 SNVs 
(point mutation) in (FMR1, CHD7, and CERBBP) and 2 In-dels (Insertion) in 
(ZNF804A, and RAI1), while there were 3 SNVs (point mutation) in (RELN-25e, 
PCDH9, and CHD*) and 1 In-del (SHANK2) detected in patient #2. In patient #3 and 
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#4 there was no any In-dels detected, on the other hand, all the variants that were 
detected were SNVs (point mutation) and were verified as follows; (MET, Dmd, 
Tsc2, and SHANK2-3) in patient #3, and (RELN-13e, LAMC3, EHMT1, and 
ANKRD11) in patient #4. 
Among the 4 patients, all the SNVs were validated by Sanger sequencing 
except AUTS2-8 and AUTS2 genes, on the other hand, only RAI1 was not validated 
by Sanger sequencing in the case of In-dels. While other 2 genes (ZNF804A, and 
SHANK2) were validated by Sanger sequencing completely, on other word, Sanger 
sequencing did not give the correct and exact variation in the exact position that was 
reported by MiSeq but it showed the correct position which guide the researcher to the 
position where there is a variation that needs a manual study. 
Specificity of the primers was not of great issue to obtain positive results of 
sequencing by using Sanger sequencing. As in our data, we found that AUTS2-8 
(AUTS2 gene-exone8) was identified and detected in patient #1 and characterized 
under the low quality variant (not real variant), it was detected by PCR (expected 
product size) but when we tried to validate it by using Sanger sequencing it did not 
work. Although the specificity of the designed primers based on using Amplyfix 
software , the designed primers (specifically the forward primer) for AUTS2 gene did 
not give a sharp sequence. This pitfall was verified by using National Center for 
Biotechnology Information- primers blast (www.ncbi.nlm.nih.gov) which clarified the 
non specificity of these primers, as it can align with different DNA sites on the same 
chromosome (chromosome 7) and/or in the different chromosomes (like chromosome 
1 and 9) which may indicate that the designed primers represent conserved sequence 
of genes of the same family. Therefore other specific primers for that gene should be 
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designed and prepared to overcome this defect. However, due to the restricted time of 
the project we exclude it.  
While in the case of AUTS2 that was identified in the patient #4 and was 
characterized under the high quality variants (real variant), it was detected by doing 
PCR but did not detected by Sanger sequencing and the sequence was not clear at all. 
There is no specific explanation for that except the sequence technical error problem 
because we repeat the sequence for this sample one time and we repeat the PCR then 
repeating the sequencing again and always it give not clear sequence and it could not 
be read at all. Because of that we exclude it as well.  
Regarding In-dels, ZNF804A that was detected by MiSeq platform on patient 
#1, Sanger sequencing validated it with the exact variation and position. Also, Sanger 
sequencing was able to validate SHANK2 that was detected by MiSeq platform on 
patient #2 which have duplication and could be difficult to be detected which is 
consistency with (Zhang et al., 2005) [56] that explained the duplication in human 
genome in details and the difficulty of detecting duplication repeats by sequencing, 
and showed a great advantage for NGS platforms that was able to detect the In-dels 
variation correctly although it is known to be great challenge for sequencing methods 
in general and NGS in particular [57].  
Sanger sequencing did not validate RAI1 that was identified on patient #1 but 
it gave the right position of variation. In MiSeq VCF file, the variation detected in 
RAI1 is the deletion of G (c.840delG), however, in the Sanger sequencing it was 
validated to be the insertion of CAG (c.838_840CAG) in the same region.  
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Actually, this issue is common in the case of in-dels that sequenced by NGS; 
and this data is consistent with the data published by Yuen et al., 2015 [58] that 
reported the inability of detecting all the In-dels by Sanger sequencing, on the other 
hand, the ability to detect only 64.3 % of all detected In-dels. The major cause of this 
problem with In-dels is DNA repeats which means the repetition of the same 
sequence many times within the same genome [59]. This repetition is present in most 
of the large genome in almost half of human genome that is in a range of 200–500 bp 
[60, 61], some of these repeats are normal (not functional) that means do not have any 
effect on the human evolution, while other repeats could play a key role in the 
evolution of the human [62, 63] although they are independent element [64, 65]. 
These repeats result during some biological mechanism that lead to creation and 
insertion of these repeats within the genome, it could be ranged from 1-2 base (mono- 
and dinucleotide) up to million of bases. They are separated in to three categorizes: 
short tandem repeats (microsatellites) and longer interspersed repeats (called short 
interspersed nuclear elements (SINEs) and long interspersed nuclear elements 
(LINEs)) [61]. 
Because of that, repeats make it really difficult in the computational 
perspective when doing the alignment with references and in genome assembly 
because it is aligned with multiple location, which will not have direct effect on the 
read mapping program, while it affect the SNPs calling. Because when alignment 
program face repeats it goes within three options; the first option is to ignore all 
repeats (multi reads), the second option is to go with the best match attitude by 
alignment to the less mismatch. If they are equal multiple best match alignment, the 
aligner will randomly pick one of them or all of them to be reported. The last choice is 
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to report the maximum number of the alignment regardless of the total number 
reported. That will result in those false positives/ negatives interpretation [57]. 
The first option will result in missing some important variation because it 
leads to discard the repeats in many multi genes families. The other two options will 
be able to pick the repetitive regions through the best match approach will be the only 
option that postulates a more realistic coverage. After that, these reads could be 
resolved manually by tools like IGV [66]and SAMtools [67], which give the 
researchers the choice of keeping or discarding the reads. However, this way is not a 
practical and useful in the case of large data. SAMtools could also be used for SNVs 
calling, that will allow finding SNVs within the repetition region which is consistent 
with our finding when did NGS for RAI1, we will be able to find point mutation A>G 
within the repetitive region. 
The most common repeats problems depend on the length of the repeats that 
are usually longer than the read length that will lead to providing gaps in the 
assembly. The second problem of repeats is that the assembler sometimes failed to 
distinguish them so the regions that are closest to them will be missed as well. To 
overcome the repeats problem, we could apply the hypothesize methods on the VCF 
file that generated by MiSeq to detect the SNVs, then after that we use other post 
processing software to detect the misassemblies such as Integrated Genomic Viewer 
(IGV) software [68]. Also for the read length problem, the alignment methods will 
depend on the depth of the coverage and the paired-end data to be able to decide if the 
variant detected is repeated region or not [69]. Also, detection of the repeats could be 
done by computational statistics on the depth of coverage for each contig, that means 
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if the desired genome is covered 20X for example, and then most contigs will be 
covered by default at 20x. So any repetitive region will be deeply covered and the 
algorithm will detect these repetitions and deal with it in different way[57].    
  In our study, there are 4 genes that were chosen randomly from the list of each 
patient to prove our hypothesized criteria in detecting the correct variants and we 
called them low quality variants. Those genes are (AUTS2-8, CDKL5) in patient #1 , 
(PON3) in patient #2, (KIRRELE3) in patient #3, and (ATRX_8) in patient #4. All of 
them are validated by Sanger sequencing except AUTS 2_8 (the reason described 
before) and give the exact sequence when aligned with the reference that were taken 
from UCSC genome browser and the normal control sample that were run along with 
the patients samples. Which prove that our criterion is validated and could be applied 
to any VCF file list that generated from MiSeq for any genetic diseases, taking the 
Autism as an example.  
In our study, we Used Sanger sequencing analysis as a gold method in the 
validation of all the variants resulted in from NGS which is consistence with many 
published papers that depend on Sanger sequencing as the known and common 
validation method. One of these studies was used Sanger sequencing in validating the 
selected samples that have novel mutation based on the data called by NGS, is the 
report published by Shao et al., 2016 [70]. Another example is the data published by 
Jiang et al., 2013 [71] that used Sanger sequencing for validation of 36 exonic 
variants detected as de novo and ASD-relevant variants in some Autism patients and 
all of them confirmed as true variants. In addition, Michaelson et al published a study 
in 2012 that supported our data of using Sanger sequencing for validation of total of 
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668 putative germline DNMs and the result was the validation of only 652 sites while 
the remaining sites gave incomplete data [72]. 
 There is some limitation that we faced during our study, first, the difficulty in 
understanding the bioinformatics tool that used for the analysis in order to develop the 
hypothesized criteria. Second, the limited amount of samples provided for us that 
didn’t allow us to repeat any PCR with the low quality result. 
For future studies, there is some recommendation that could be done. We 
could study the failing or low quality variants in order to have a complete pipeline 
that we can relay on and be more confident that we will not going to miss any 
variant. Also some molecular studies could be done for the detected variants, as 
well as, study the protein structure for the detected mutations and do some 
functional studies for better understanding of its pathophysiologic role in the 
developed disease. 
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6. Conclusion: 
Next generation sequencing (NGS) and specifically targeted capture exome or 
genes were established as a time efficient and cost effective tool for sequencing and 
detecting the genetic causes for multifaceted genetic diseases and simple genetic 
disease.[73, 74]. NGS used for sequencing of high throughput data, these data could 
be up to kilobases or megabases. NGS not only used for diagnosis of genetic diseases, 
but also it could have a great application in the field of personalized medicine, that 
help in understanding the response of specific individuals to infectious diseases, to 
vaccinations, and particular immunosuppressive drugs[48]. 
Targeted region capture methods, is a direct method that aid in escalating the 
ability to detect the rare variants that will be difficult and costly detected by normal 
and common methods like Sanger sequencing. Although Targeted region capture 
methods are considered as a great discovery in the field of sequencing, but this will 
not reduce the impact of using Sanger sequencing as a gold standard method for 
validation of variants or mutations that are generated from NGS. This result from the 
challenge that NGS faced in specificity and sensitivity of data generated, which is still 
no clear cut criteria are available to be used by NGS to ensure that all the variants that 
are generated from any platform of the NGS are true and there are no false positives 
or false negatives are included in the list.  
In our research, we were able to establish a filtering pipeline that was able to 
reduce the false positive significantly. Also we were able to validate the filtered list 
resulted by the hypothesized pipeline and prove it is efficacy in detecting rare variants 
correctly with reducing the cost of validating all the list generated by MiSeq platform. 
Also, we chosen some random variants that were passed according to MiSeq platform 
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but failed according to our hypothesized criteria and we were able to prove that our 
criteria were correct and worked well and all these detected variants were normal and 
gives the same sequence as a control. Our future plane is to check the failing variants 
to evaluate the false negatives variants that may be missed due to an analysis by 
MiSeq platform; also we could solve the detection of In-dels by using more specific 
criteria that work specifically on In-dels to ease detecting them. After establishing 
such a criteria we could claim that this criterion good and effective to be used for 
filtering data of VCF file generated by MiSeq platform.    
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